Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdvanDrop Med is a liquid formulation that utilizes AdvanDrop™ technology to significantly improve the solubility and oral bioavailability of cannabinoids, primarily Cannabidiol (CBD), in aqueous solutions. This technology aims to accelerate and potentiate the effects of CBD on the body by enhancing its absorption into the bloodstream, leading to a higher concentration and faster action compared to standard CBD oils. Cannabidiol (CBD) is a non-psychotropic cannabinoid that interacts with the endocannabinoid system (ECS) and other receptors. Its complex mechanism of action involves modulating cannabinoid receptors (CB1 and CB2), acting as an agonist on transient receptor potential cation channel subfamily V member 1 (TRPV1) and 5-hydroxytryptamine receptor 1A (5-HT1A), and as an antagonist on G protein-coupled receptor 55 (GPR55). This enhanced delivery system is developed by Healthcann.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AdvanDrop Med.